Disease · HP_0000737
Irritability
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Irritability. Diseases, record HP_0000737. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000737
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Irritability
- Open Targets ID
- HP_0000737
- Other names
- Cranky, Easily annoyed, Easily bothered, Easily upset, Grumpy, Hot-temper, Irritable, Quick temper, Short fuse, Short tempered
- Highest stage of its drugs
- Approval, for 5 of its 32 drugs, from PMDA and TTD
Source Open Targets
Drugs32
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ARIPIPRAZOLE | CHEMBL1112 | Small molecule | Approval | PMDA | 3 | 2 | 2 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| TALBUTAL | CHEMBL1200802 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| TETRAHYDROPALMATINE | CHEMBL487182 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| BREXPIPRAZOLE | CHEMBL2105760 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LUMATEPERONE | CHEMBL3306803 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXTROMETHORPHAN | CHEMBL52440 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LURASIDONE | CHEMBL1237021 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| QUINIDINE | CHEMBL1294 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 32
See all 32 drugsTargets82
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | 7 | Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist | Approval | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 6 | Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6332 | Drugs and targets |
1 to 10 of 82
See all 82 targetsTrials30
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05523895 | Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder | Phase 2/3 | 237 | 2025-08-24 | Irritability Associated With Autism Spectrum Disorder | PIMAVANSERIN | Its record names the disease | ClinicalTrials.gov |
| NCT05555615 | Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder | Phase 2/3 | 209 | 2025-12-03 | Irritability Associated With Autism Spectrum Disorder | PIMAVANSERIN | Its record names the disease | ClinicalTrials.gov |
| NCT00779324 | Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study | Not applicable | 168 | 2021-09-10 | Brain Injury, Aggression | AMANTADINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03095066 | Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury | Phase 2 | 168 | 2025-10-29 | Neurobehavioral Disinhibition | DEUDEXTROMETHORPHAN HYDROBROMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01911442 | Lurasidone Pediatric Autism Study | Phase 3 | 150 | 2016-02-25 | Autism | LURASIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT04174365 | Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder | Phase 3 | 119 | 2025-08-28 | Irritability Associated With Autism Spectrum Disorder (ASD) | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02507284 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | Phase 2 | 106 | 2023-07-20 | Irritable Mood, Huntington's Disease | SRX246 | Its record names the disease | ClinicalTrials.gov |
| NCT00794040 | A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation | Phase 2 | 103 | 2019-05-07 | Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder | CITALOPRAM, METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT04258839 | Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 | Phase 3 | 95 | 2024-05-30 | Irritability Associated With Autism Spectrum Disorder | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01617460 | A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder | Phase 3 | 86 | 2017-10-20 | Autistic Disorder | ARIPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All AVP-786 vs All Placebo: deaths from any cause | 0 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| All AVP-786 vs All Placebo: serious adverse events | 3 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| Amantadine vs Placebo: serious adverse events | 3 of 82 | 2 of 86 | 168 | NCT00779324 | Trial comparisons |
| STX209 vs Placebo: serious adverse events | 1 of 63 | 0 of 63 | 126 | NCT00788073 | Trial comparisons |
| Brexpiprazole vs Placebo: deaths from any cause | 0 of 58 | 0 of 57 | 115 | NCT04174365 | Trial comparisons |
| Brexpiprazole vs Placebo: serious adverse events | 0 of 58 | 0 of 57 | 115 | NCT04174365 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) | 4 of 49 | 2 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: deaths from any cause | 0 of 49 | 0 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values | 6 of 49 | 4 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: serious adverse events | 2 of 49 | 1 of 46 | 95 | NCT04258839 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42162607 | DERIVED | 1 | PubMed |
| 41499296 | DERIVED | 1 | PubMed |
| 41103807 | DERIVED | 1 | PubMed |
| 38145314 | DERIVED | 1 | PubMed |
| 37811711 | DERIVED | 4 | PubMed |
| 31128268 | DERIVED | 1 | PubMed |
| 29742960 | DERIVED | 1 | PubMed |
| 29644582 | DERIVED | 1 | PubMed |
| 28941259 | DERIVED | 1 | PubMed |
| 28891908 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000737
GET https://conductscience.org/api/diseases/v1/HP_0000737/drugs?page=2